Changqing Xie, M.D., Ph.D.

Changqing Xie, M.D., Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
Thoracic and GI Malignancies Branch


I am interested in exploring the potential mechanism of resistance to treatment with immune checkpoint inhibitor in gastrointestinal (GI) malignancy. My focus is to dissect the role of cancer stem cells in cholangiocarcinoma in terms of developing this therapy resistance.

Areas of Expertise

Gastrointestinal (GI) Malignancy
Immune Checkpoint Inhibitors

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them. 


Selected Publications

Clinical Indicators for Long-Term Survival with Immune Checkpoint Therapy in Advanced Hepatocellular Carcinoma

Monge C, Xie C, Steinberg SM, Greten TF
J Hepatocellular Carcinoma. 8: 507-512, 2021. [ Journal Article ]

Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis

Fu J, Li W-Z, McGrath NA, Lai CW, Brar G, Xiang Y-Q, Xie C
Frontiers In Oncology. 11: 650292, 2021. [ Journal Article ]

Immunotherapy of Hepatocellular Carcinoma with Infection of Hepatitis B or C Virus

Monge Bonilla C, McGrath NA, Fu J, Xie C
Hepatoma Research. 6: 68, 2020.

Systemic treatment options for advanced biliary tract carcinoma

Xie C, McGrath NA, Monge Bonilla C, Fu J
Journal of Gastroenterology. 55(10): 944-957, 2020. [ Journal Article ]

Targeting cancer stem cells in cholangiocarcinoma (Review)

McGrath NA, Fu J, Gu SZ, Xie C
International Journal of Oncology. 57(2): 397-408, 2020. [ Journal Article ]

Job Vacancies

There are no open positions at this time. Check back again later, or take a look at CCR's Careers page.


Postbaccalaureate Fellow (CRTA)
Xin Wang


Jianyang Fu
Jianyang Fu
Nicole McGrath
Nicole McGrath


Learn more about CCR research advances, new discoveries and more on our news section.